Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia.

Research output: Contribution to journalArticle

Standard

Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. / Craddock, Charles; Labopin, M; Pillai, Srinivas; Finke, J; Bunjes, D; Greinix, H; Ehninger, G; Steckel, NK; Zander, AR; Schwerdtfeger, R; Buchholz, S; Kolb, HJ; Volin, L; Fauser, A; Polge, E; Schmid, C; Mohty, M; Rocha, V.

In: Leukemia, Vol. 25, No. 5, 01.05.2011, p. 808-13.

Research output: Contribution to journalArticle

Harvard

Craddock, C, Labopin, M, Pillai, S, Finke, J, Bunjes, D, Greinix, H, Ehninger, G, Steckel, NK, Zander, AR, Schwerdtfeger, R, Buchholz, S, Kolb, HJ, Volin, L, Fauser, A, Polge, E, Schmid, C, Mohty, M & Rocha, V 2011, 'Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia.', Leukemia, vol. 25, no. 5, pp. 808-13. https://doi.org/10.1038/leu.2011.13

APA

Craddock, C., Labopin, M., Pillai, S., Finke, J., Bunjes, D., Greinix, H., Ehninger, G., Steckel, NK., Zander, AR., Schwerdtfeger, R., Buchholz, S., Kolb, HJ., Volin, L., Fauser, A., Polge, E., Schmid, C., Mohty, M., & Rocha, V. (2011). Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia, 25(5), 808-13. https://doi.org/10.1038/leu.2011.13

Vancouver

Author

Craddock, Charles ; Labopin, M ; Pillai, Srinivas ; Finke, J ; Bunjes, D ; Greinix, H ; Ehninger, G ; Steckel, NK ; Zander, AR ; Schwerdtfeger, R ; Buchholz, S ; Kolb, HJ ; Volin, L ; Fauser, A ; Polge, E ; Schmid, C ; Mohty, M ; Rocha, V. / Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. In: Leukemia. 2011 ; Vol. 25, No. 5. pp. 808-13.

Bibtex

@article{18b64d6159884cafac2c7350c1483b7c,
title = "Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia.",
abstract = "Treatment options for adults with primary refractory acute myeloid leukaemia (PREF AML) are extremely limited. Although sibling allogeneic stem cell transplantation can result in long-term survival, most patients lack a matched family donor and are destined to die of refractory disease. Greater availability of unrelated donors and improvements in supportive care have increased the proportion of patients with PREF AML in whom allografting is technically feasible, but the outcome of unrelated donor transplantation in this population has not been studied. We therefore analysed overall survival in 168 patients with PREF AML, who underwent unrelated donor transplantation between 1994 and 2006. The 5-year overall survival for the whole group was 22%. In multivariate analysis, fewer than three courses of induction chemotherapy, a lower percentage of bone marrow blasts at transplant and patient cytomegalovirus seropositivity were associated with improved survival. This allowed the development of a scoring system that identified four groups with survival rates between 44±11% and 0%. This study demonstrates an important role for unrelated donor transplantation in the management of selected patients with PREF AML and confirms the importance of initiating an urgent unrelated donor search in patients with no matched sibling donor, who fail to respond to induction chemotherapy.",
author = "Charles Craddock and M Labopin and Srinivas Pillai and J Finke and D Bunjes and H Greinix and G Ehninger and NK Steckel and AR Zander and R Schwerdtfeger and S Buchholz and HJ Kolb and L Volin and A Fauser and E Polge and C Schmid and M Mohty and V Rocha",
year = "2011",
month = may,
day = "1",
doi = "10.1038/leu.2011.13",
language = "English",
volume = "25",
pages = "808--13",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

RIS

TY - JOUR

T1 - Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia.

AU - Craddock, Charles

AU - Labopin, M

AU - Pillai, Srinivas

AU - Finke, J

AU - Bunjes, D

AU - Greinix, H

AU - Ehninger, G

AU - Steckel, NK

AU - Zander, AR

AU - Schwerdtfeger, R

AU - Buchholz, S

AU - Kolb, HJ

AU - Volin, L

AU - Fauser, A

AU - Polge, E

AU - Schmid, C

AU - Mohty, M

AU - Rocha, V

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Treatment options for adults with primary refractory acute myeloid leukaemia (PREF AML) are extremely limited. Although sibling allogeneic stem cell transplantation can result in long-term survival, most patients lack a matched family donor and are destined to die of refractory disease. Greater availability of unrelated donors and improvements in supportive care have increased the proportion of patients with PREF AML in whom allografting is technically feasible, but the outcome of unrelated donor transplantation in this population has not been studied. We therefore analysed overall survival in 168 patients with PREF AML, who underwent unrelated donor transplantation between 1994 and 2006. The 5-year overall survival for the whole group was 22%. In multivariate analysis, fewer than three courses of induction chemotherapy, a lower percentage of bone marrow blasts at transplant and patient cytomegalovirus seropositivity were associated with improved survival. This allowed the development of a scoring system that identified four groups with survival rates between 44±11% and 0%. This study demonstrates an important role for unrelated donor transplantation in the management of selected patients with PREF AML and confirms the importance of initiating an urgent unrelated donor search in patients with no matched sibling donor, who fail to respond to induction chemotherapy.

AB - Treatment options for adults with primary refractory acute myeloid leukaemia (PREF AML) are extremely limited. Although sibling allogeneic stem cell transplantation can result in long-term survival, most patients lack a matched family donor and are destined to die of refractory disease. Greater availability of unrelated donors and improvements in supportive care have increased the proportion of patients with PREF AML in whom allografting is technically feasible, but the outcome of unrelated donor transplantation in this population has not been studied. We therefore analysed overall survival in 168 patients with PREF AML, who underwent unrelated donor transplantation between 1994 and 2006. The 5-year overall survival for the whole group was 22%. In multivariate analysis, fewer than three courses of induction chemotherapy, a lower percentage of bone marrow blasts at transplant and patient cytomegalovirus seropositivity were associated with improved survival. This allowed the development of a scoring system that identified four groups with survival rates between 44±11% and 0%. This study demonstrates an important role for unrelated donor transplantation in the management of selected patients with PREF AML and confirms the importance of initiating an urgent unrelated donor search in patients with no matched sibling donor, who fail to respond to induction chemotherapy.

U2 - 10.1038/leu.2011.13

DO - 10.1038/leu.2011.13

M3 - Article

C2 - 21339758

VL - 25

SP - 808

EP - 813

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -